<DOC>
	<DOCNO>NCT00971100</DOCNO>
	<brief_summary>The present study , randomize , single-blind , dose-ranging , multicenter study , evaluate immunogenicity , safety tolerability two dos adjuvanted not-adjuvanted new swine-origin influenza A/H1N1 virus monovalent subunit vaccine healthy child adolescent . A booster dose administer 12 month first vaccination .</brief_summary>
	<brief_title>Immunogenicity , Safety Tolerability Two Doses Adjuvanted Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine Healthy Subjects From 6 Months 17 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males females 6 month age 17 year age day enrollment ; 2 . Subject 's parent legal guardian give write consent subject give assent consent , applicable ; 3 . Individuals good health ; 4 . Subjects , subject 's parent legal guardian able comply study procedure ; 5 . Willingness allow serum sample store beyond study period , potential additional future test good characterize immune response . 1 . Subject 's parent legal guardian able comprehend follow require study procedure ; 2 . Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study ; 3 . Individuals serious chronic progressive disease accord judgment investigator ; 4 . History anaphylaxis , serious vaccine reaction excipients egg ( include ovalbumin ) chicken protein ; 5 . Individuals adjuvanted influenza vaccine document confirm suspected influenza disease within 3 month prior Day 1 . 6 . Receipt another investigational agent within 4 week prior enrollment completion safety followup period another study , unwilling refuse participation another clinical study end study ; 7 . Individuals receive vaccine 4 week prior enrolment study plan receive vaccine within four week study vaccine ; exception plain seasonal influenza vaccine allow one week prior one week study vaccination ; 8 . Individuals receive blood , blood product and/or plasma derivative parenteral immunoglobulin preparation past 12 week ; 9 . Individuals axillary temperature â‰¥ 38.0 degree Celsius within 3 day intend study vaccination ; 10 . Known suspected alteration immune function ; 11 . History progressive severe neurologic disorder ; 12 . Surgery plan study period Investigator 's opinion would interfere study visit schedule ; 13 . If female , childbearing potential , use `` acceptable contraceptive method '' least 2 month prior study entry ; 14 . Females pregnant nursing ( breastfeed ) mother , female childbearing potential plan use acceptable birth control measure first 3 week vaccination ; 15 . Members research staff relatives .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Pandemic influenza</keyword>
	<keyword>Vaccine</keyword>
</DOC>